Treatment of acute myelogenous leukemia in children
Tóm tắt
Progress in the treatment of childhood AML has not equalled the advances obtained in the management of ALL. Two recent chemotherapy studies (i.e. VAPA and BFM 78), however, reported marked increase in the proportion of long-term remissions. The initial therapy of the cooperative study BFM 78 consisted of two 4-week phases of intensive induction/consolidation with 7 different drugs and cranial irradiation followed by maintenance with thioguanine and cytosine arabinoside for 2 years and additional adriamycin during the first year. A total of 151 children with AML were enrolled in the study from 30 centers. Of these 119 (79%) patients achieved complete remission. After a median observation time of 34 (14–57) months, there have been 46 relapses. CNS was involved in 6 of these relapses. Life table analyses revealed the following probabilities after 4 1/2 years: survival: 46%; disease-free survival: 41% (total group), 52% (remission group); disease-free interval 56% (remission group). The risk of relapse appears to decrease considerably after 2 1/2 years. No risk factors for the occurrence of relapse have been identified.
Tài liệu tham khảo
Henze G, Langermann H J, Gadner H, Schellong G, Welte K, Riehm H: Ergebnisse der Studie BFM 76/79 zur Behandlung der akuten lymphatischen Leukämie bei Kindern und Jugendlichen.Klin Pädiat 193, 145 (1981).
Riehm H, Gadner H, Henze G, Kornhuber B, Langermann, H J, Müller-Weihrich St, Schellong G: Acute lymphoblastic leukemia: treatment results in three BFM studies (1970–1981). InLeukemia Research: Advances in Cell Biology and Treatment, Murphy S M and Gilbert J R (eds), pp. 251–263. Amsterdam, Elsevier (1983).
Madanat F F, Sullivan M P: Improved survival in young children with acute granulocytic leukemia with combination therapy using cyclophosphamide, oncovin, cytosine arabinoside and prednisone.Cancer 44, 819 (1979).
Plüss H J, Hitzig W H: Die akuten myeloischen Leukämien in Kindesalter—Behandlungsresultate 1964–1979.Schweiz med Wschr 110, 1459 (1980).
Chard R L, Finkelstein J Z, Sonley M J, Nesbit M, McCreadie S, Weiner J, Sather H, Hammond D: Increased survival in childhood acute nonlymphocytic leukemia after treatment with prednisone, cytosine arabinoside, 6-thioguanine, cyclophosphamide, and oncovin (PATCO) combination chemotherapy.Med Pediatr Oncol 4, 263 (1978).
Baehner R L, Bernstein I D, Sather H, Higgins G, McCreadie S, Chard R L, Hammond D: Improved remission induction rate with D-ZAPO but unimproved remission duration with addition of immunotherapy to chemotherapy in previously untreated children with ANLL.Med Pediatr Oncol 7, 127 (1979).
Dahl G V, Kalwinsky D K, Murphy S, Look A T, Amadori S, Kumar M, Novak R, George S L, Mason C, Mauer A M, Simone J V: Cytokinetically based induction chemotherapy and aplenectomy for childhood acute nonlymphocytic leukemia.Blood 60, 856 (1982).
Weinstein H J, Mayer J R, Rosenthal D S, Camitta B M, Coral F S, nathan D G, Frei E III: Treatment of acute myelogenous leukemia in children and adults.New Engl J Med 303, 473 (1980).
Weinstein H J, Mayer J R, Rosenthal D S, Coral F S, Camitta B M, Gelber R D: Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update.Blood 62, 315 (1983).
Creutzig U, Ritter J, Langermann H J, Riehm H, Henze G, Niethammer D, Jürgens H, Stollmann B, Lasson U, kabisch H, Wahlen W, Löffler H, Schellong G: Akute myeloische leukämie bei Kindern: Ergebnisse der cooperativen Therapiestudie BFM-78 nach 3 3/4 Jahren.Klin Pädiat 196, 152 (1983).
Scheer U, Schellong G, Riehm H: Verbesserte Prognose der akuten myeloischen Leukämien bei Kindern nach intensivierter Anfangstherapie.Klin Pädiatr 191, 210 (1979).
Lampkin B C, Woods W, Strauss R, Feig St, Higgins G, bernstein I, D’Angio G, Chard R, Bleyer A, Hammond D: Current Status of the Biology and Treatment of Acute Non-Lymphocytic Leukemia in Children’s (Report from the ANLL Strategy Group of Children’s Cancer Study Group).Blood 61, 215 (1983).
Bennett J.M. Catovsky D, Daniel M-Th, Flandrin G, Galton D A G, Gralnick H R, Sultan C: Proposals for the classification of the leukemias.Br J Haemat 33, 451 (1976).
Kaplan E, Meier O: Nonparametric estimation from incomplete observations.J Am Statist Assoc 53, 457 (1983).
Cavalli F: VP 16-213 (Etoposide): a critical review of its activity.Cancer Chemother Pharmac 7, 81 (1982).
Schmoll H J, Niederle N, Achterrath W: Etoposid (VA 16-213), eine antineoplastische Substanz aus der Reihe der Podophyllotoxin.Klin Wschr 59, 1117 (1981).
Büchner T, Urbanitz D, Emmerich B, Fischer J T, Füller H H, Heinecke A, Hossfeld D K, Koeppens K M, Labedzki L, Löffler H, Nowrousian M R, Pfreundschuh M, Pralle H, Rühl H, Wendt F C, for the AML cooperative group: Multicentre study on intensified remission induction therapy for acute myeloid leukemia.Leukemia Res 6, 827 (1982).
Thomas, E D, Clift R A, Buckner C D: Marrow transplantation for patients with acute nonlymphoblastic leukemia who achieve a first remission.Cancer Treatment Rep 66, (1982).